Similar articles

• Effect of piracetam on sickle erythrocytes and sickle hemoglobin.

  Asakura T, Ohnishi ST, Adachi K, Ozguc M, Hashimoto K, Devlin MT, Schwartz E. Asakura T, et al. Biochim Biophys Acta. 1981 May 29;668(3):397-405. doi: 10.1016/0005-2795(81)90173-2. Biochim Biophys Acta. 1981. PMID: 7236716
• Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam.

  Nalbandian RM, Henry RL, Burek CL, Diglio CA, Goldman AI, Taylor GW, Hoffman WH. Nalbandian RM, et al. Am J Hematol. 1983 Sep;15(2):147-51. doi: 10.1002/ajh.2830150206. Am J Hematol. 1983. PMID: 6613985
• Effects of piracetam and iodoacetamide on erythrocyte sickling.

  Costa FF, Zago MA, Bottura C. Costa FF, et al. Lancet. 1979 Dec 15;2(8155):1302. doi: 10.1016/s0140-6736(79)92315-8. Lancet. 1979. PMID: 93216 No abstract available.
• Blockade of adhesion of sickle cells to endothelium by monoclonal antibodies.

  Hebbel RP. Hebbel RP. N Engl J Med. 2000 Jun 22;342(25):1910-2. doi: 10.1056/NEJM200006223422512. N Engl J Med. 2000. PMID: 10861330 Review. No abstract available.
• Cyanate as an inhibitor of red-cell sickling.

  Cerami A. Cerami A. N Engl J Med. 1972 Oct 19;287(16):807-12. doi: 10.1056/NEJM197210192871606. N Engl J Med. 1972. PMID: 4560520 Review. No abstract available.